Laki Power Closes Financing Led By Brunnur Ventures
28.10.2019 09:00:00 EET | Business Wire | Press release
Laki Power (www.lakipower.com), a leader in real-time surveillance for high-voltage powerline infrastructure, announced today the successful closing of its first institutional investment round, led by Brunnur Ventures. The new capital will support further development of the Company’s high-voltage powerline sensor product portfolio, powered by its unique patent-pending line energy harvesting platform.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191027005046/en/
Inductively powered and sited directly on the phase wire, our LKX-range of sensors provides fully-autonomous, next-generation monitoring capabilities for high-voltage transmission and distribution infrastructure. (Photo: Business Wire)
“We’re pleased to announce the closing of this funding and are delighted to be working with the experienced team at Brunnur Ventures,” said Sigurjon Magnusson, CEO at Laki Power. “This round enables us to accelerate the build out of our power harvesting capabilities into an expanded range of high-value products and services that address the rapidly growing needs of power grid operators for real-time knowledge of system health and functionality.”
Electricity grids worldwide are changing, driven by the increased demands of distributed generation of wind and solar, and pressure from both customers and regulators for increased resilience, transparency and accountability.
“Addressing the need for real-time, actionable intelligence for the monitoring and management of power grid infrastructure is clearly a huge opportunity and we are seeing that utilities are deploying sensing and monitoring systems more broadly, and faster than ever before,” commented Arni Blöndal, General Partner at Brunnur Ventures.
Unique capabilities
Laki Power’s unique products are powered by the only on-market energy harvester that supports multiple sensors and communications devices with full autonomy from external power sources, eliminating the need for solar, wind or diesel generators. The Company’s PowerGRAB™ technology harvests energy from the electromagnetic field surrounding the alternating current (AC) carrying phase wires of high voltage power lines to provide direct current (DC) power for running external and internal surveillance and monitoring devices, and many other applications that need clean and stable DC power.
About Laki Power
Laki Power was founded in 2015 to transform the way line monitoring is carried out for transmission system operators (TSOs) and distribution system operators (DSOs), by bringing to market new technology that dramatically enhances the level of power that can be efficiently harvested from high voltage lines.
Electrical transmission and distribution systems worldwide span millions of kilometres. Yet despite carrying huge amounts of energy, tapping into that energy, to provide monitoring devices with power in the remote places that these lines cross, has remained a persistent challenge. Instead these systems have relied on local fossil fuel generators, wind turbines, solar cells or power from the line that requires a mini-substation to adapt voltage and power levels for proper utilization. This results in very high costs of installing, maintaining and resupplying these systems, as well as a host of other environmental, operational, logistical and maintenance issues.
Laki Power's patent pending technology can harvest up to hundred times more power than competitor solutions, offering unprecedented monitoring capacity and flexibility for a range of sensors and applications.
For more information, please visit: www.lakipower.com
About Brunnur Ventures
Brunnur Ventures is a $30m venture capital fund focused on Icelandic start-up companies, emphasizing innovation and growth, combined with scalable business models and extraordinary entrepreneurial talent.
For more information, please visit: www.brunnurventures.com
Laki Power and the Laki Power logo are registered trademarks of Laki Power in the United States and/or other countries. The names of actual companies and products mentioned herein may be the trademarks of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191027005046/en/
Contact information
Sigurjon Magnusson
CEO, Laki Power
sigurjon.magnusson@lakipower.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 12:47:00 EEST | Press release
Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food products. Within this inspiring premise, Good Food Makers confirms itself as one of the main levers f
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 11:16:00 EEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom